A Randomized Phase II Trial of Intermittent Versus Continuous

The primary objective of this study is to compare progression-free survival with intermittent dosing and continuous dosing of dabrafenib and trametinib among patients with metastatic BRAFV600E/K mutant melanoma.

September 25, 2015

  • Clinical Trial Information

    Trial Contact: Beal, Daniel; Frankos, Marie

    Trial Phone: 321.841.4347 ; 321-841-7303

  • Age Group: Adult

    Phase: Drug: Phase II

    Principal Investigator: Sajeve Samuel Thomas, MD

    Sub Investigators: N/A

    IRB No:

    Secondary Protocol No: S1320

    Applicable Disease Sites: Melanoma